{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(3)"],"submitter":["Jonasch E"],"pubmed_abstract":["Anti-angiogenic agents, such as vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors and anti-VEGF antibodies, and immune checkpoint inhibitors (CPIs) are standard treatments for advanced renal cell carcinoma (aRCC). In the past, these agents were administered as sequential monotherapies. Recently, combinations of anti-angiogenic agents and CPIs have been approved for the treatment of aRCC, based on evidence that they provide superior efficacy when compared with sunitinib monotherapy. Here we explore the possible mechanisms of action of these combinations, including a review of relevant preclinical data and clinical evidence in patients with aRCC. We also ask whether the benefit is additive or synergistic, and, thus, whether concomitant administration is preferred "],"journal":["Cancers"],"pagination":["644"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8833428"],"repository":["biostudies-literature"],"pubmed_title":["Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?"],"pmcid":["PMC8833428"],"pubmed_authors":["Jonasch E","Chowdhury S","Mainwaring P","Atkins MB"],"additional_accession":[]},"is_claimable":false,"name":"Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?","description":"Anti-angiogenic agents, such as vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors and anti-VEGF antibodies, and immune checkpoint inhibitors (CPIs) are standard treatments for advanced renal cell carcinoma (aRCC). In the past, these agents were administered as sequential monotherapies. Recently, combinations of anti-angiogenic agents and CPIs have been approved for the treatment of aRCC, based on evidence that they provide superior efficacy when compared with sunitinib monotherapy. Here we explore the possible mechanisms of action of these combinations, including a review of relevant preclinical data and clinical evidence in patients with aRCC. We also ask whether the benefit is additive or synergistic, and, thus, whether concomitant administration is preferred ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-04-08T17:48:37.857Z","creation":"2025-04-20T00:22:21.032Z"},"accession":"S-EPMC8833428","cross_references":{"pubmed":["35158916"],"doi":["10.3390/cancers14030644"]}}